Results 11 to 20 of about 18,827 (200)

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance [PDF]

Cancer Biology & Medicine, 2019
Objective Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zheng Wei Wong, Iuan Sheau Chin, Pei San Yee, Chai Phei Gan, Kein Seong Mun, Zainal Ariff Abdul Rahman, J. Silvio Gutkind, Vyomesh Patel, Sok Ching Cheong   +10 more
doaj   +2 more sources

Updates on managing advanced breast cancer with palbociclib combination therapy

Therapeutic Advances in Medical Oncology, 2018
Background: The objective of this study was to review the pharmacology, efficacy, and safety of palbociclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of advanced breast cancer (ABC).
Teresa M. McShane, Thomas A. Wolfe, Joanne C. Ryan   +2 more
doaj   +2 more sources

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Current Issues in Molecular Biology
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor and a commonly used antitumor drug. Many cancers are susceptible to palbociclib resistance, however, the underlying metabolism mechanism and extent of resistance to palbociclib are unknown.
Lulu Yang, Yajun Yue, Zhendong Wang, You Jiang, Zhichao Xue, Yongzhuo Zhang   +5 more
doaj   +2 more sources

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

PLoS ONE, 2019
The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li, Xuehong Zhang, Liankun Gu, Jing Zhou, Dajun Deng   +4 more
doaj   +2 more sources

TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression

Cell Death Discovery
Palbociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer by suppressing cell proliferation. However, monotherapy with palbociclib was discouraging in prostate cancer, calling for a mechanism-based effective therapy. In this study, we
Yangyi Zhang, Chenyu Liu, Yalan Yang, He Ren, Tianyi Ren, Yinuo Huang, Shinan Zhang, Qiang Sun, Hongyan Huang   +8 more
doaj   +2 more sources

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models [PDF]

Molecular Therapy: Nucleic Acids, 2022
Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT ...
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini   +9 more
doaj   +2 more sources

In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments [PDF]

Drug Design, Development and Therapy
Wenyu Du,1,2 Zihan Liu,1,2,* Ying Li,2,* Zhi Wang,2 Zhanjun Dong2 1Graduate School, Hebei Medical University, Shijiazhuang, 050017, People’s Republic of China; 2Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy ...
Du W, Liu Z, Li Y, Wang Z, Dong Z
doaj   +1 more source

Lenvatinib and Palbociclib [PDF]

Hospital Pharmacy, 2015
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A, Solimando, J Aubrey, Waddell
openaire   +2 more sources

Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS. [PDF]

Cancers (Basel)
Background. Ductal carcinoma in situ (DCIS) is a non-invasive disease of the breast. This study assessed the impact of the CDK4/6 inhibitor palbociclib on halting cell cycle progression in DCIS between diagnostic biopsy and surgical resection of the ...
Battina R, Mainor C, Schmidt MO, Gallanis GT, Sharif GM, Walsh E, Whitaker K, Greenwalt I, Cruz L, Swanson N, Bouker KB, Wellstein A, Isaacs C, Pohlmann PR, Riegel AT.   +14 more
europepmc   +2 more sources

Rational design of a lipophilic β-galactosidase-responsive near-infrared probe for in vivo imaging of cellular senescence. [PDF]

Smart Mol
We developed a lipophilic near‑infrared probe (DCIP‑AcGal) that is specifically activated by senescence‑associated β‑galactosidase. After intravenous injection, it lights up therapy‑induced tumor senescence in living mice. Its optimized lipophilicity also enables blood‑brain barrier crossing to detect natural brain senescence ex vivo. This probe offers
Huang J, Chu F, Feng B, Chen L, Cen P, Wang J, Qu Y, Hong L, Wu F, Tian H, Fang Y, Chen Y, Tian M, Zeng W, Zhang H, Zhong Y.   +15 more
europepmc   +2 more sources